Showing posts with label COVID-19. Show all posts
Showing posts with label COVID-19. Show all posts

Monday, May 10, 2021

Vitamin D deficiency in India




With this review, we aim to summarize the existing literature on Vitamin D status in India and understand the enormity of the problem. The prevalence of Vitamin D deficiency ranged from 40% to 99%, with most of the studies reporting a prevalence of 80%–90%. 


Urban India is shunning the sunlight and in the process, grappling with an epidemic — a deficiency of Vitamin D. With or without symptoms, doctors are diagnosing almost every urban Indian with the deficiency of a vitamin that is manufactured in the body when the skin is exposed to sunlight. Vitamin D helps in the absorption of calcium and its deficiency can lead to bone diseases such as osteoporosis along with other muscle and nerve-related diseases. It also increases the chances of developing diabetes. Vitamin D deficiency prevails in epidemic proportions all over the Indian subcontinent, with a prevalence of 70%–100% in the general population. In India, widely consumed food items such as dairy products are rarely fortified with vitamin D. Indian socio-religious and cultural practices do not facilitate adequate sun exposure, thereby negating the potential benefits of plentiful sunshine. Consequently, subclinical vitamin D deficiency is highly prevalent in both urban and rural settings, and across all socioeconomic and geographic strata. Vitamin D deficiency is likely to play an important role in the very high prevalence of rickets, osteoporosis, cardiovascular diseases, diabetes, cancer, and infections such as tuberculosis in India. Fortification of staple foods with vitamin D is the most viable population-based strategy to achieve vitamin D sufficiency. Unfortunately, even in advanced countries like the USA and Canada, food fortification strategies with vitamin D have been only partially effective and have largely failed to attain vitamin D sufficiency. This article reviews the status of vitamin D nutrition in the Indian subcontinent and also the underlying causes for this epidemic. Implementation of population-based educational and interventional strategies to combat this scourge requires recognition of vitamin D deficiency as a public health problem by the governing bodies so that healthcare funds can be allocated appropriately.



A 2019 pan-India study found that 70-90 percent of Indians are deficient in the sunshine vitamin, and the deficiency can have adverse consequences for skeletal development in babies and children, and bone health in adults. The study was authored by diabetologist PG Talwalkar, and Vaishali Deshmukh, MC Deepak, and Dinesh Agrawal. It noted that the deficiency is linked to chronic diseases, including diabetes, hypertension, and cardiovascular disease. The study found that 84.2 percent of Type II diabetes patients were Vitamin D deficient, 82.6 percent of hypertension patients. It noted that there is no significant variation in deficiency levels across North, South, East, or West regions, with each reporting deficiency prevalence of 88 percent, 90 percent, 93 percent, and 91 percent respectively.


Dr. Sushila Kataria, Senior Director of Internal Medicine at Medanta The Medicity, Gurugram, agrees that vitamin D deficiency has been a long-prevalent issue in India anyway and that we should be vigilant about these levels throughout the year, lockdown or not. Dr. Kataria explains that in certain amounts of UV light, cholesterol in the blood gets converted into vitamin D, adding, “It acts like a hormone, helping in calcium homeostasis and, in turn, bone and muscle strength, as well as optimizing the nervous system.” There are two sub-sects of vitamin D: D2 (found in plants) and D3 (found in fatty animal sources). But Dr. Kataria says that it is difficult to find abundant sources of both in India, hence the need for fortified foods.




Mumbai-based Tanvi Dalal, the founder of WellNest Nutrition, recommends her clients to take multivitamin supplements, adding, “Many people, without testing their levels, assume they are eating a lot of vitamin D-rich foods, such as one piece of salmon for dinner or a whole bowl of cereal which is fortified with vitamin D. These portions are not enough; matching up to 800 IU is very tough. A can of tuna can claim to have 500 IU, but you will not eat the whole can, only two tablespoons most likely. For people, up to 70 years of age, between 600 to 800 IU of vitamin D is required, and the multivitamin covers this exactly, without going over or under.” Tanvi says it’s best to spend between 30 minutes and an hour on the balcony or terrace, between 11 am and 2 pm when the sun is at its nexus. The big key here is to not wear any SPF. Sunscreen-lovers may balk at such a suggestion, but Tanvi affirms that SPF will filter out your sunlight exposure and stop vitamin D production. If you are prone to sunburn, opt for shorter bursts through this period.



Both vitamin D and B12 deficiencies are related to depression and anxiety, especially at this time. Medically, before prescribing an anti-anxiety tablet, your doctor may check these levels, and prescribe a supplement along with psychotherapy. Spending at least half an hour in sunlight with exposure of face and arms is the minimum requirement to fight the deficiency apart from taking supplements that are mostly harmless. Infants should get exposed to the sun, at least 10 to 15 mins a day, which generates 10 to 20,000 Vitamin D units. Along with that, experts also suggest Vitamin D supplements until the age of 1 year depending on the condition to combat the deficiency. Zeljko Serdar, CCRES



Wednesday, April 29, 2020

The coronavirus COVID-19 stay in human body permanent



The line between truth and lies is becoming ever murkier. It’s possible the virus sticks around in the body longer than expected, because patients still testing positive for the virus after they have recovered or even getting sick again. 



People who appear to recover and then show symptoms again may have suffered a relapse of the same infection.  Patients produced thousands to millions of viruses in their noses and throats, about 1,000 times as much virus as produced in SARS patients, that heavy load of viruses may help explain why the new coronavirus is so infectious.

These results could also reflect issues with the current diagnostic test, which isn’t sensitive enough to always pick up low levels of virus in an infected person. One has to tell the truth.

The novel coronavirus, the pathogen that causes COVID-19, can remain in the body of an infected person for years and requires lifelong medication, as with the infection of hepatitis B, where a patient is a chronic carrier of the virus. For hepatitis B patients, antibodies are constantly generated to neutralize the viruses.
If antibodies cannot be detected, it is because viruses are constantly replicating and antibodies are generated to neutralize them. Otherwise, it indicates viruses have been deactivated.

For most people, medicine treatment can't cure chronic hepatitis B, only suppressing the replication of the virus. Therefore, most people who start treatment must continue it for life.

Based on experience from SARS and MERS and AIDS, virus covid- 19 stay in human body permanent. On patients after they have recovered the researchers could still detect the virus’s genetic material, RNA, in patients’ swabs or samples, but could no longer find infectious viruses.
That’s an indication that antibodies that the body’s immune system makes against SARS-CoV-2 are killing viruses that get out of cells.

Monday, April 20, 2020

Testing for the coronavirus (COVID-19)



Testing for the coronavirus (COVID-19) has varied widely across countries. To reduce the risk of new outbreaks, countries will need to greatly increase their testing capacity. 


A  key  question  behind  any  strategy  to  ease confinement  restrictions  and  reopen  economic activities is how to avoid a new spread of the SARS-CoV-2 virus that would necessitate further lock downs.  Once the  number  of  infected  people  has  successfully  been  brought  sufficiently down, quick  suppression  of new  waves  of  viral  infections  will  be  key.  Testing  strategies  are central to achieve this.

There are two types of tests.

First, molecular diagnostic testing (RT-PCR) helps to identify those individuals who are infected at the time of the test. An effective strategy that tests, tracks people infected and traces their contacts (TTT), helps to reduce the spread of the virus and thus bring its reproduction number below one.
Given the characteristics of this coronavirus–including the large number of asymptomatic cases and high reproduction number –to be effective at suppressing the spread of the virus, the TTT strategy should be used very widely, requiring a very large proportion of all cases (between 70 and  90%) to be traced to  prevent  a new outbreak of the  virus. This  would require increasing capacity for testing enormously; putting in places trict measures to prevent people who may be infectious from breaking quarantine; as well as identifying ways to trace contacts,which may push the limits of privacy concerns, unless new approaches to digital tracing, currently under development, are put in place.
Significant logistics and capacity constraints –ranging from the availability of trained personnel to  take  accurate  specimen,  to  the  time  required  for  laboratory  analysis  and  the  availability  of reagents –have impeded more widespread diagnostic testing in many countries so far. Recent development of faster RT-PCR molecular diagnostic testing, which can be deployed at the point of care, should help scale-up capacity for  effective TTT in countries. Digital  enabled contact-tracing can  help  improve  the  speed  and  effectiveness  of  TTT  strategies,  as  seen  in  some countries.

A second type of test –so-called serologic test –detects people who have had a prior infection and  thus  developed  antibodies.  Such  tests  can  be  used  for  two  purposes,  namely  to  allow people who have acquired immunity to return to work safely, and to provide intelligence on the evolution of the epidemic across the population. Rapid serology test kits need to be developed and  their  clinical  performance  needs  to  be  demonstrated  before  deployment  at  scale  can happen.
Despite the fact that a relatively low number of people have so far been infected and thus we are still far from herd immunity, the successful implementation of serologic testing strategies at large scale can help reduce the spread of the virus and complement the TTT strategy.

This will also require major efforts, including: 

1) verifying the clinical performance of tests, particularly for rapid  serologic  tests; 

2) preparing  procurement  and  logistics  arrangements  to  scale  up production and deployment of the tests, and train and deploy human resources, particularly for diagnostic RT-PCR tests; and

3) providing adequate safeguards to protect civil right and privacy of populations while deploying or apps-enabled tracking strategies.

Since the end of last year, the world has been in the grip of the SARS-CoV-2 virus, which has caused tens of thousands of deaths from the respiratory disease COVID-19. To combat the pandemic, many countries have put in place strict containment and mitigation strategies to minimise the risk of transmission, decrease the spread of the virus and ‘buy time’ for health care systems to cope with the huge numbers of patients and ultimately save as many lives as possible. As part of the response to COVID-19, virtually all OECD countries affected by the virus have introduced strict restrictions to social and economic life, including social distancing and even full lock downs. The big question  is  now  how  to  manage  these  restrictions,  and  how  to  go  back  to  a new  normal of  living  with SARS-CoV-2; a social and economic life that coexist with the virus. To avoid new peaks in the number of cases, overstretching health system capacities, infection rates need to remain suppressed until a vaccine or  effective  treatment  are  found.  If  all  confinement  strategies  are  lifted,however,  the  infection  rate  is expected to rebound in a matter of weeks. A strategy is needed about when and how to relax confinement, and when and how to re-tighten some of them when necessary. This is needed to minimise the risk of further peaks of the outbreak or, at least, to win as much time as possible between the successive peaks.

A number of factors need to be in place to achieve this goal. 

First, healthcare capacity and resources need to be increased to ensure safe and effective management of future severe COVID-19 cases.

Second, we need to understand the virus better, including: the incubation period and infectiousness of the disease  at  different  stages;  the  extent  of  asymptomatic  spread;  immunity  and  its  duration  in  those  who contracted the virus; and the impact of changes in temperature on the disease spread.

Third –and the topic of this brief –information about the presence and propagation of SARS-CoV-2 in the population  needs  to  improve  significantly. For  this,  widespread  testing  and  effective  contact  tracing, including cases with no or only mild symptoms, are key components of the post-lock down strategy. Better information will help achieve three goals:

Tracking of new cases to suppress the resurgence of local outbreaks as early as possible, aiming to avoid new peaks;

Identifying previously infected people who can safely return to work, to revitalise the economy and to strengthen the health workforce;

Gaining  intelligence  on  the  evolution  of  the  epidemic,  including  on  when a  threshold  for herd immunity has been reached.In the case of COVID-19, it has been estimated that 50% to 60% of the population needs to be immune to the virus to halt its spread.

The Organisation for Economic Co-operation and Development (OECD) is an international organisation that works to build better policies for better lives. Together with governments, policy makers and citizens, work on establishing evidence-based international standards and finding solutions to a range of social, economic and environmental challenges. From improving economic performance and creating jobs to fostering strong education and fighting international tax evasion, provide a unique forum and knowledge hub for data and analysis, exchange of experiences, best-practice sharing, and advice on public policies and international standard-setting.


More info at: Tackling coronavirus (COVID‑19)
Contributing to a global effort


Zeljko Serdar, CCRES

PS.
The OECD Teaching and Learning International Survey (TALIS) is an international, large-scale survey of teachers, school leaders and the learning environment in schools. This note presents findings based on the reports of lower secondary teachers and their school leaders in mainstream public and private schools. CROATIA





Friday, April 17, 2020

Pan-European Privacy-Preserving Proximity Tracing


Pan-European Privacy Preserving Proximity Tracing Initiative
EU consortium led by Germany’s Fraunhofer Heinrich Hertz Institute for telecoms (HHI)  release software code that can be used to create apps that will help track transmission chains of COVID-19.  The Pan-European Privacy Preserving Proximity Tracing (“PEPP-PT”) project comprises more than 130 members across eight European countries, including scientists, technologists, and experts.
The PEPP-PT project has published a manifesto explaining its intention to create “well-tested proximity tracking technologies” that national authorities can use to create their own COVID-19 apps.  According to the manifesto, these technologies ensure “secure data anonymization” and “cross border interoperability”.  The apps concerned would inform users, based on the phone’s Bluetooth signals, whether they have been in the proximity of a person who was tested positive for COVID-19.
National public authorities developing apps on the basis of this software remain free to decide how to inform persons that have been in contact with someone who has tested positive.  The PEPP-PT website states that national cyber security agencies and national data protection agencies will assess the apps that are created using the code released by the PEPP-PT.  EU Commissioner Thierry Breton indicated that the European Commission is also investigating whether an app using the PEPP-PT software would be compliant with “EU values”, reflecting the privacy concerns associated with such apps.
Several Member States have been considering using apps in the fight against COVID-19 (e.g.Ireland and Germany).  Polish authorities, for example, have developed an app that individuals who tested positive for COVID-19, and are in quarantine, can voluntary use to prove that they remain in quarantine (i.e., by sending selfies with their location to the authorities), as an alternative to receiving police visits.
COVID-19 Apps and Websites
Since the start of the COVID-19 crisis in Europe, private and public entities have begun releasing COVID-19 related apps.  In response, some EU Supervisory Authorities have issued statements in relation to such apps:
  • The Belgian Supervisory Authority provided brief guidance to developers of COVID-19 apps (and websites). It clarifies the expected standard of anonymity and, in particular, it states that IP addresses should always be considered as personal data. It also distinguishes apps offered by healthcare providers and other health apps.  In the latter case, the apps should provide at the time of set up, and before any personal data is collected or shared, all the information required by Article 13 of the GDPR. According to the statement, “at the end of the use of the application”, all personal data should be deleted. 

Italy RAI news yesterday:

https://www.rainews.it/dl/rainews/articoli/coronavirus-app-scelta-tracciamento-accordo-piattaforma-immuni-87df3c01-2f2b-459b-9d66-24eb053de8ae.html

  • The Italian Supervisory Authority states that it “would have no objection” to an app managed by public authorities that tracks persons who tested positive with COVID-19 and people who have come into contact with such persons, provided the app complies with data protection law.
  • The German Supervisory Authority of Rhineland-Palatinate states that an app that tracks the transmission of COVID-19 using Bluetooth technology “is possible”, provided it complies with data protection law. The statement lists various criteria that, in the opinion of the authority, are decisive in order to comply with data protection law.  In particular, the authority notes that use of the app should be voluntary, the purposes for processing the data be limited, that pseudonymization techniques are applied to the data and that the data be deleted if there is no longer a risk of infection.
  • The Slovenian Supervisory Authority issued a statement about the website https://covid-19-stats.si/, which allowed individuals to report and record their COVID-19 symptoms, provide information about the symptoms, indicate the number of family members in the individual’s household, record the date symptoms were first detected, and the individual’s phone number and residential information. Despite claiming that it only collected anonymized data, the authority’s investigation revealed that the data was only encrypted and not anonymized and therefore did not comply with the GDPR.  As a result, the website announced that it has deleted its database and is looking into how to provide this service in a GDPR-compliant manner.  The same authority issued a statement on the use of geolocation data to fight COVID-19, which states that this is only possible in exceptional circumstances and provided appropriate safeguards are in place.
  • The Spanish Supervisory Authority states that only public authorities have the authority to process personal data to control the epidemic. This includes collecting data in order to offer self-assessment tools and the collection of geolocation data for creating maps of high/low risk areas, or to control whether individuals who have tested positive comply with quarantine restrictions.  Private entities may only process personal data pursuant to the instructions of the public health authorities.
In general, the statements released by EU Supervisory Authorities so far suggest that the use of apps or websites by public authorities to track the spreading of COVID-19 will be allowed, provided they comply with the principles found in EU data protection laws.  By contrast, regulators appear far more skeptical that private-sector bodies should be deploying and using such apps or websites.  CCRES will continue to monitor these developments closely.



From the Pan-European Privacy-Preserving Proximity Tracing web site:

Pan-European Privacy-Preserving Proximity Tracing
(PEPP-PT) makes it possible to interrupt new chains of SARS-CoV-2 transmission rapidly and effectively by informing potentially exposed people. 
We are a large and inclusive European team. We provide standards, technology, and services to countries and developers. We embrace a fully privacy-preserving approach. We build on well-tested, fully implemented proximity measurement and scalable backend service. We enable tracing of infection chains across national borders. 

PEPP-PT was created to assist national initiatives by supplying ready-to-use, well-tested, and properly assessed mechanisms and standards, as well as support for interoperability, outreach, and operation when needed.

The PEPP-PT mechanisms will have these core features:
  1. Well-tested and established procedures for proximity measurement on popular mobile operating systems and devices.
  2. Enforcement of data protection, anonymization, GDPR compliance, and security.
  3. International interoperability to support tracing local infection chains even if a chain spans multiple PEPP-PT participating countries.
  4. Scalable backend architecture and technology that can be deployed with local IT infrastructure.
  5. Certification service to test and ensure local implementations use the PEPP-PT mechanisms in a secure and interoperable manner.
  6. Our reference implementation is available under the Mozilla License Agreement.
To find out more about the additional services we offer to support infrastructure and installation campaigns to enable country-specific applications, please download our Manifesto. 

The virus has spread quickly and knows no political boundaries. To bring it under control, we must act in the same manner; speed and international cooperation are essential to protect health, privacy, and the economy.
Find out more about our view of the current situation and why we believe proximity-tracing is the appropriate solution to resuming a normal life, opening our borders, and restarting the economy.

We invite all countries to participate and use what we have to offer. We are stronger together against SARS-CoV-2. Please contact us if you are interested in using our services or contributing. 

We are establishing a partner management team to help you get going quickly.

As a partner, you will:
… have access to our services and mechanisms.
… have access to our documentation and the source code of a reference implementation.
… take part in the inter-country exchange that will make our lives global again.
… provide feedback on the technical design.
… encourage your country to support PEPP-PT development and deployment.
… obtain certification for your implementation through PEPP-PT and thus inherit our privacy and security certifications and credentials.
… provide your national cyber-security, data protection, and health agencies with a solution that saves the effort of building certified services from scratch.
… receive planning and financial aid for installation and trust campaigns in your country.
… receive planning and execution aid for integrating PEPP-PT into your country’s strategy.


You can either implement PEPP-PT directly using the provided app/trust service reference implementation and add country-specific aspects
OR
Integrate PEPP-PT technology into an existing solution through the modules in our  services.

Please get in touch.
We welcome you on board.

WHO WE ARE
PEPP-PT is an organization that will be incorporated as a non-profit in Switzerland. PEPP-PT was created to provide a solution to this crisis that adheres to strong European privacy and data protection laws and principles. The PEPP-PT technical mechanisms and standards fully protect privacy while taking advantage of the possibilities of digital technology to maximize the speed and real-time capability of national pandemic responses. Our goal is to make this technology available to all countries, managers of infectious disease responses, and developers as quickly and seamlessly as possible.



The PEPP-PT team, which as of 31st March 2020,  has more than 130 members across eight European countries, includes scientists, technologists, and experts from well-known international research institutions and companies. We have expertise in communication, psychology, epidemiology, proximity tracing, security, privacy, encryption, data protection, application development, scalable systems, supercomputing infrastructure, and artificial intelligence.


PePP-PT e.V. i.Gr
c/o Hans-Christian Boos
Eisenmannstr 3
80331 München

Telefon: +49-69-40568-200
E-Mail: info@pepp-pt.org

Das Impressum gilt für: pepp-pt.org
Registergericht:  Antrag gestellt
Registernummer: noch nicht erteilt

The supervisory authority responsible for PePP-PT e.V. i.Gr. is:

Bayerisches Landesamt für Datenschutzaufsicht (BayLDA)
Promenade 27, 91522 Ansbach, Germany
Telephone: +49 (0) 981 53 1300
Fax: +49 (0) 981 53 98 1300